Edition:
United States

Inovio Pharmaceuticals Inc (INO.A)

INO.A on American Stock Exchange

6.24USD
19 Oct 2017
Change (% chg)

$-0.09 (-1.42%)
Prev Close
$6.33
Open
$6.26
Day's High
$6.27
Day's Low
$6.24
Volume
406
Avg. Vol
--
52-wk High
$6.99
52-wk Low
$5.36

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 2.95
Market Cap(Mil.): $563.92
Shares Outstanding(Mil.): 90.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.36 16.99
EPS (TTM): -- -- --
ROI: -- 2.41 11.25
ROE: -- 3.35 15.06

BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine

* Inovio Pharmaceuticals Inc ‍reported on positive safety and immune response results from phase 1 trial of a vaccine against zika virus​

Oct 05 2017

BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

* Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

Sep 18 2017

BRIEF-Inovio’s cancer immunotherapy slowed PSA rise and increased PSA doubling times in patients with recurrent prostate cancer

* Inovio’s cancer immunotherapy (ino-5150) slowed PSA rise and significantly increased psa doubling times in patients with recurrent prostate cancer

Sep 11 2017

BRIEF-Inovio Pharmaceuticals reports Q2 loss per share $0.13

* Inovio Pharmaceuticals reports 2017 second quarter financial results

Aug 08 2017

BRIEF-Inovio Pharmaceuticals prices 12.5 mln share offering at $6 per share

* Inovio announces pricing of public offering of common stock

Jul 19 2017

BRIEF-Inovio Pharmaceuticals says co has about $92 mln of cash and cash equivalents and short-term investments - SEC Filing

* Inovio Pharmaceuticals Inc - As Of June 30, co has about $92.0 million of cash and cash equivalents and short-term investments - SEC Filing Source text: [http://bit.ly/2vzazOH] Further company coverage:

Jul 18 2017

BRIEF-Inovio announces proposed public offering of common stock

* Inovio Pharmaceuticals Inc - intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering

Jul 18 2017

BRIEF-Inovio begins phase 3 clinical trial of VGX-3100

* Inovio begins phase 3 clinical trial of VGX-3100 for the treatment of HPV-related cervical pre-cancer

Jun 08 2017

BRIEF-Inovio Zika vaccine prevents persistence of virus and damage in male reproductive tract in pre-clinical study

* Inovio zika vaccine prevents persistence of virus and damage in male reproductive tract in pre-clinical study

Jun 07 2017

BRIEF-Inovio announces clinical trial collaboration to evaluate t-cell immunotherapy in combination with a PD-l1 checkpoint inhibitor

* Inovio announces clinical trial collaboration to evaluate a novel t-cell immunotherapy in combination with a PD-l1 checkpoint inhibitor

Jun 01 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.47 +0.43
Novartis AG (NOVN.S) CHF84.55 +0.20
Pfizer Inc. (PFE.N) $36.28 +0.04
Merck & Co., Inc. (MRK.N) $63.75 --
Sanofi SA (SASY.PA) €84.41 +0.15
GlaxoSmithKline plc (GSK.L) 1,521.50 -14.50
AstraZeneca plc (AZN.L) 5,189.00 +14.00

Earnings vs. Estimates